The 10-second takeaway
For the quarter ended Jan. 31 (Q2), Cantel Medical beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share expanded significantly.
Margins grew across the board.
Cantel Medical reported revenue of $97.3 million. The two analysts polled by S&P Capital IQ looked for a top line of $94.5 million on the same basis. GAAP reported sales were 20% higher than the prior-year quarter's $81.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.27. The two earnings estimates compiled by S&P Capital IQ predicted $0.25 per share. GAAP EPS of $0.27 for Q2 were 23% higher than the prior-year quarter's $0.22 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 42.0%, 330 basis points better than the prior-year quarter. Operating margin was 13.5%, 260 basis points better than the prior-year quarter. Net margin was 7.5%, 40 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $96.3 million. On the bottom line, the average EPS estimate is $0.25.
Next year's average estimate for revenue is $384.5 million. The average EPS estimate is $1.02.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 109 members out of 131 rating the stock outperform, and 22 members rating it underperform. Among 42 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 38 give Cantel Medical a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cantel Medical is buy, with an average price target of $22.67.
The health-care investing landscape is littered with also-rans and a few major winners. Is Cantel Medical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Cantel Medical to My Watchlist.